Your browser is no longer supported. Please, upgrade your browser.
CRVS Corvus Pharmaceuticals, Inc. monthly Stock Chart
CRVS [NASD]
Corvus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.51 Insider Own5.00% Shs Outstand29.50M Perf Week-5.74%
Market Cap114.46M Forward P/E- EPS next Y-1.55 Insider Trans-51.43% Shs Float23.39M Perf Month2.07%
Income-44.40M PEG- EPS next Q-0.31 Inst Own62.60% Short Float6.53% Perf Quarter5.07%
Sales- P/S- EPS this Y6.80% Inst Trans-15.22% Short Ratio1.73 Perf Half Y7.65%
Book/sh1.44 P/B2.74 EPS next Y-7.60% ROA-64.00% Target Price- Perf Year25.08%
Cash/sh1.77 P/C2.23 EPS next 5Y- ROE-79.10% 52W Range1.01 - 6.88 Perf YTD-27.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-42.73% Beta1.90
Dividend %- Quick Ratio4.40 Sales past 5Y- Gross Margin- 52W Low290.10% ATR0.19
Employees52 Current Ratio4.40 Sales Q/Q- Oper. Margin- RSI (14)44.94 Volatility4.05% 4.89%
OptionableYes Debt/Eq0.00 EPS Q/Q11.30% Profit Margin- Rel Volume0.22 Prev Close3.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume883.28K Price3.94
Recom1.60 SMA20-3.15% SMA50-3.77% SMA20011.61% Volume193,161 Change-0.25%
Sep-12-19Initiated Mizuho Buy
May-29-19Initiated ROTH Capital Buy $6
Aug-24-17Upgrade Credit Suisse Underperform → Neutral
May-01-17Downgrade Credit Suisse Neutral → Underperform
Apr-18-16Initiated Guggenheim Buy
Apr-18-16Initiated Credit Suisse Outperform
Nov-11-20 04:05PM  
Nov-09-20 08:05AM  
Nov-02-20 08:00AM  
Nov-01-20 09:08AM  
Oct-29-20 04:00PM  
08:30AM  
Oct-07-20 10:39AM  
Oct-05-20 09:57AM  
09:48AM  
08:05AM  
07:24AM  
07:22AM  
Sep-17-20 03:01AM  
Sep-11-20 08:30AM  
Sep-10-20 08:30AM  
Sep-08-20 06:02PM  
Aug-04-20 04:05PM  
Aug-03-20 11:33AM  
Jul-30-20 04:02PM  
Jul-23-20 08:30AM  
Jul-20-20 03:30PM  
Jul-09-20 08:43AM  
Jul-08-20 10:22AM  
09:58AM  
Jul-07-20 09:53AM  
09:32AM  
08:51AM  
07:00AM  
Jul-03-20 06:12PM  
Jun-24-20 08:40AM  
May-29-20 08:00AM  
May-27-20 08:00AM  
May-20-20 12:00PM  
May-13-20 05:23PM  
May-04-20 07:26AM  
Apr-30-20 04:05PM  
Apr-22-20 08:30AM  
Mar-10-20 05:14PM  
Mar-05-20 04:05PM  
Feb-28-20 04:01PM  
Feb-19-20 04:05PM  
Feb-13-20 08:00AM  
Feb-01-20 02:00PM  
Dec-20-19 10:56AM  
Dec-17-19 06:28AM  
Dec-07-19 09:00AM  
Nov-08-19 07:00AM  
Nov-07-19 08:30AM  
Nov-05-19 08:30AM  
Nov-04-19 08:30AM  
Nov-02-19 01:01AM  
Oct-29-19 04:05PM  
Oct-18-19 11:01AM  
Oct-17-19 08:30AM  
Oct-03-19 08:30AM  
Sep-03-19 01:28PM  
Aug-10-19 11:17AM  
Aug-07-19 04:05PM  
Aug-01-19 04:05PM  
Jul-24-19 04:15PM  
Jul-03-19 11:14AM  
Jun-02-19 10:45AM  
May-28-19 08:30AM  
May-25-19 01:28PM  
May-16-19 08:30AM  
May-09-19 05:05PM  
04:02PM  
May-01-19 04:10PM  
Apr-26-19 03:07PM  
Mar-07-19 04:10PM  
Mar-05-19 04:15PM  
Feb-06-19 08:30AM  
Jan-30-19 08:30AM  
Jan-28-19 04:05PM  
Jan-22-19 12:05PM  
Jan-10-19 08:30AM  
Jan-08-19 08:30AM  
Dec-28-18 08:52AM  
Nov-23-18 09:03AM  
Nov-13-18 07:30AM  
Nov-12-18 08:30AM  
Nov-10-18 05:00PM  
Nov-05-18 06:31PM  
Nov-02-18 05:12AM  
Nov-01-18 04:10PM  
Oct-22-18 08:30AM  
Oct-04-18 04:15PM  
Oct-03-18 04:15PM  
07:46AM  
Sep-25-18 04:15PM  
Aug-02-18 06:45PM  
04:15PM  
Jul-31-18 04:15PM  
Jun-28-18 08:30AM  
May-30-18 04:15PM  
May-03-18 07:35PM  
04:10PM  
Apr-26-18 08:30AM  
Mar-19-18 07:40AM  
Mar-12-18 09:15AM  
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical trial of CPI-006 for COVID-19; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2-inducible T-cell kinase, that is Phase I/Ib clinical trial. Corvus Pharmaceuticals, Inc. also entered into a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was founded in 2014 and is based in Burlingame, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novo Holdings A/S10% OwnerJul 08Sale5.37741,4403,985,1661,389,498Jul 09 04:35 PM
Novo Holdings A/S10% OwnerJul 07Sale5.25796,6224,183,3812,130,938Jul 09 04:35 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.